Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study
暂无分享,去创建一个
[1] K. Sung,et al. Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users , 2019, Journal of clinical medicine.
[2] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[3] Daniel E Forman,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[4] James R. Staley,et al. Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and non-linear mendelian randomisation analyses , 2019, BMJ.
[5] A. Khera,et al. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results From the Cooper Center Longitudinal Study , 2018, Circulation.
[6] Sang Min Park,et al. Association of change in total cholesterol level with mortality: A population-based study , 2018, PloS one.
[7] Jennifer G. Robinson,et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.
[8] B. Nordestgaard,et al. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies , 2017, European heart journal.
[9] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[10] James R. Staley,et al. Semiparametric methods for estimation of a nonlinear exposure‐outcome relationship using instrumental variables with application to Mendelian randomization , 2017, bioRxiv.
[11] B. Nordestgaard,et al. Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014. , 2017, Atherosclerosis.
[12] F. Kronenberg,et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.
[13] S. Thompson,et al. Instrumental Variable Analysis with a Nonlinear Exposure–Outcome Relationship , 2014, Epidemiology.
[14] L. Bathum,et al. Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: A population-based register study , 2013, Scandinavian journal of primary health care.
[15] B. Nordestgaard,et al. Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids. , 2012, Danish medical journal.
[16] Patrick Royston,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[17] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[18] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[19] K. Christensen,et al. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. , 2010, Age and ageing.
[20] R. Mayeux,et al. Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. , 2008, Age and ageing.
[21] W. Howard. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .
[22] J. Greenberg. Correcting Biases in Estimates of Mortality Attributable to Obesity , 2006, Obesity.
[23] J. Staessen,et al. Low‐Density Lipoprotein Cholesterol and Mortality in Older People , 2005, Journal of the American Geriatrics Society.
[24] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[25] R. Mayeux,et al. Relationship Between Plasma Lipids and All‐Cause Mortality in Nondemented Elderly , 2005, Journal of the American Geriatrics Society.
[26] T. Lumley,et al. The Association Between Lipid Levels and the Risks of Incident Myocardial Infarction, Stroke, and Total Mortality: The Cardiovascular Health Study , 2004, Journal of the American Geriatrics Society.
[27] Elinor Miller,et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.
[28] R. Collins,et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.
[29] M. Trabucchi,et al. Serum cholesterol levels as a measure of frailty in elderly patients. , 1998, Experimental aging research.
[30] R A Kronmal,et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. , 1998, JAMA.
[31] K C Cain,et al. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. , 1993, Archives of internal medicine.
[32] S. Yusuf,et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.